ALK and non-small cell lung carcinoma: While the data on the use of ALK inhibitors in ESCC are limited, five ALK inhibitors have been approved for the treatment of non-small-cell lung cancer with an ALK rearrangement, and while the outlook has significantly improved, the emergence of drug resistance remains a significant challenge.